Emotional breakthrough and psychedelics : Validation of the Emotional Breakthrough Inventory Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato, Mendel Kaelen, Rosalind Watts and Robin Carhart-Harris Journal of Psychopharmacology, 2019, 1–12 DOI: 10.1177/0269881119855974 Abstract Background : Psychedelic therapy is gaining recognition and the nature of the psychedelic experience itself has been found to mediate subsequent long-term psychological changes. Much emphasis has been placed on the occurrence of mystical-type experiences in determining long-term responses to psychedelics yet here we demonstrate the importance of another component, namely: emotional breakthrough. Methods : Three hundred and seventy-nine participants completed online surveys before and after a planned psychedelic experience. Items pertaining to emotional [...]
Lire la suiteThe Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity Ido Hartogsohn Frontiers in Neurosciences, 06 March 2018 | https://doi.org/10.3389/fnins.2018.00129 Past research has demonstrated to the ability of psychedelics to enhance suggestibility, and pointed to their ability to amplify perception of meaning. This paper examines the existing evidence for the meaning-enhancing properties of psychedelics, and argues that the tendency of these agents to enhance the perception of significance offers valuable clues to explaining their reported ability to stimulate a variety of therapeutic processes, enhance creativity, and instigate mystical-type experiences. Building upon previous research, which suggested the potential role of [...]
Lire la suitePeter Webster added a comment to the article : REBUS and the Anarchic Brain : Toward a Unified Model of the Brain Action of Psychedelicss R. L. Carhart-Harris and K. J. Friston, Pharmacological Reviews, 2019, 71, 316–344 https://doi.org/10.1124/pr.118.017160 https://www.grecc.org/publications/ressources-documentaires/pharmacologie/rebus-and-the-anarchic-brain-toward-a-unified-model-of-the-brain-action-of-psychedelics-r-l-carhart-harris-and-k-j-friston-2019/ Prediction : ultimately you will find that the Salience Network has a far greater importance for understanding psychedelic experience than the DMN. See: Menon V. (2015) Salience Network. In: Arthur W. Toga, editor. Brain Mapping: An Encyclopedic Reference, vol. 2, p. 597. Academic Press: Elsevier. In Doors of Perception, Aldous Huxley writes, [I was seeing] a bunch of flowers shining with their own inner light and all but quivering under the [...]
Lire la suiteIbogaine and Subjective Experience : Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder Thomas K. Brown, PhDa, Geoff E. Noller, PhDb, and Julie O. Denenberg, MAc Journal of Psychoactive Drugs, 2019 https://doi.org/10.1080/02791072.2019.1598603 ABSTRACT This article examines the therapeutic potential of ibogaine, a powerful oneiric alkaloid derived from Tabernanthe iboga, through exploring the subjective experiences of 44 participants from two observational treatment studies for opioid use disorder. Following treatment with ibogaine HCl, the participants (Mexico, n = 30; New Zealand, n = 14) completed the States of Consciousness Questionnaire (SCQ) to quantify the magnitude of their psychotropic experience. Participants were asked to provide [...]
Lire la suite'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape, October 20, 2017 https://www.medscape.com/viewarticle/887384 Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at [...]
Lire la suitePsychedelic Cuts Cravings, Consumption in Alcohol Use Disorder Pauline Anderson Medscape, May 23, 2019 https://www.medscape.com/viewarticle/913422?src=wnl_tp10n_190711_mscpedit&uac=292598PZ&impID=2023688&faf=1 SAN FRANCISCO — Just two doses of the psychedelic drug psilocybin, taken over a period of 8 weeks, significantly reduced alcohol use and cravings in patients with alcohol use disorder, preliminary findings show. In the first study to use modern clinical trial design to investigate the effects of a hallucinogen in alcohol-dependent patients, investigators at New York University (NYU) School of Medicine in New York City found that use of psilocybin was significantly associated with fewer drinking days and fewer drinks per day, as well fewer cravings. Dr Kelley Clark O'Donnell "Psychedelic [...]
Lire la suiteFirst, Marijuana. Are Magic Mushrooms Next ? Barbara Feder Ostrov Medscape - May 21, 2018 In Oregon and Denver, where marijuana is legal for recreational use, activists are now pushing toward a psychedelic frontier: “magic mushrooms.” Groups in both states are sponsoring ballot measures that would eliminate criminal penalties for possession of the mushrooms whose active ingredient, psilocybin, can cause hallucinations, euphoria and changes in perception. They point to research showing that psilocybin might be helpful for people suffering from depression or anxiety. “We don’t want individuals to lose their freedom over something that’s natural and has health benefits,” said Kevin Matthews, the campaign director [...]
Lire la suitePsychedelic-assisted therapy for anxiety and depression in the face of death: A critical review with an anthropological lens Jenna VARLEY Journal of Psychedelic Studies, 2019, 3, (1), 14–18. DOI: 10.1556/2054.2019.005 Psychedelics have been investigated for their therapeutic applications in end-of-life care as early as 1960. Recently, there have been four main groups conducting clinical trials for either lysergic acid diethylamide or psilocybin for the treatment of anxiety and depression in patients with terminal illnesses. The recent trials have higher methodological quality and demonstrate the profound impact of psychedelics for this particular patient presentation. However, a number of gaps, including understanding the meaning of death [...]
Lire la suiteIntercultural, intermolecular : An ethnobotanical examination of the potential therapeutic value of LSD for the treatment of depression Karsten FATUR Journal of Psychedelic Studies, 2019, 3, (1), 32–34. DOI: 10.1556/2054.2019.002 Lysergic acid diethylamide holds great therapeutic potential in the treatment of depression, although currently illegal in many parts of the world and seen as a recreational drug. An intercultural ethnobotanical examination of plant substances with similar chemical profiles and effects displays the true potential value of this substance and justifies an increased focus on clinical trials and studies involving it. Keywords : psychedelic, LSD, ayahuasca, depression, serotonin Despite its current status as an illegal substance, lysergic [...]
Lire la suiteLong-lasting analgesic effect of the psychedelic drug changa : A case report Genis ONA and Sebastian TRONCOSO Journal of Psychedelic Studies, 2019, 3, (1), 7–13. DOI: 10.1556/2054.2019.001 Background and aims : Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa, a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods : We describe the case and offer a brief review of supportive findings. Results : A long-lasting analgesic effect after [...]
Lire la suite